We also provide evidence that RelA/p65′s tumour promoting action in NSCLC is due to, at least in part, the downregulation of CD82 that inhibits cell migration and EMT, and the stimulation of ERK and Rac1 through the engagement of integrin-mediated signalling as revealed by bioinformatics analysis. The gene discussed is CD82; the disease is non-small cell lung carcinoma.